palivizumab 50 MG per 0.5 ML Injection

RxCUI
1657361
RxNorm name
palivizumab 50 MG per 0.5 ML Injection
Display name
palivizumab 50 MG per 0.5 ML Injection
Full name
palivizumab 50 MG per 0.5 ML Injection
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:38:54

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
103770Synagispalivizumab351(a)Disc2026-10-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
3a0096c7-8139-44cd-bba4-520ab05c2cb2palivizumab 50 MG in 0.5 ML Injection [PSN] · 0.5 ML palivizumab 100 MG/ML Injection [SCD] · palivizumab 50 MG per 0.5 ML Injection [SY]38These highlights do not include all the information needed to use SYNAGIS safely and effectively. See full prescribing information for SYNAGIS. SYNAGIS ® (palivizumab) injection, for intramuscular use Initial U.S. Approval: 199820260121